Halia Therapeutics is a clinical-stage biotechnology company developing first-in-class therapies that target inflammation at its source. Our pipeline is built on a deep understanding of genetic resilience—natural human mutations that protect against disease by shutting down harmful inflammatory pathways. HT-6184, our lead program, is an oral NEK7/NLRP3 inflammasome modulator with compelling Phase 2 data in myelodysplastic syndromes (MDS). In partnership with UAE national genomics initiatives. HT-4253, our LRRK2 inhibitor, is advancing toward a precision-medicine Phase 2 in genetically defined early Alzheimer’s disease. We operate across the U.S. and the Middle East, leveraging global clinical networks, genetic databases, and regulatory pathways to accelerate therapeutic development in inflammation-driven diseases.